Lupin receives tentative approval from USFDA for Oxcarbazepine ER Tablets
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
The CDMO upgrade represents a transformational step for Remedium Lifecare
EBITDA before special items decreases to €4.08 billion (7.4%)
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Subscribe To Our Newsletter & Stay Updated